Positron emission tomography (PET) has become an indispensable tool in the study of cancer biology, as well as in the clinical
management of patients with cancer. Quantitative measurements of tracer accumulation enable researchers to detect tumor changes much
earlier than by conventional imaging modalities. 18F-FDG has been widely utilized for staging and restaging of cancer, evaluation of response
to the treatment, and assessment of prognosis; however, recently target-specific PET tracers have raised even more attention. This
overview discusses the current status of PET imaging in optimization of cancer therapies in preclinical and clinical studies.
Keywords: Molecular imaging, PET, 18F-FDG, cancer therapy, cancer biology, prognosis, metastasize, CNS response, radionuclide, cell proliferation
Rights & PermissionsPrintExport